Полная версия

Главная arrow Медицина arrow Внутренние болезни: заболевания желудочно-кишечного тракта

  • Увеличить шрифт
  • Уменьшить шрифт


<<   СОДЕРЖАНИЕ   >>

РЕКОМЕНДУЕМАЯ ЛИТЕРАТУРА

Основная

  • 1. Комаров Ф.И., Осадчук А.М., Осадчук М.А., Кветной И.М. Неспецифический язвенный колит. М.: Медицинское информационное агентство, 2008.
  • 2. Пальцева М.А., Паукова В.С.. Патология: учебник в 2 т. / Под ред. М.А. Пальцева, В.С. Пауковой. М. : ГЭОТАР-Медиа, 2011. 512 с.

Дополнительная

  • 3. Baki Е., Zwickel Р., Zawierucha A., Ehehalt R., Gotthardt D., Stremmel W., Gauss A. Real-life outcome of anti-tumor necrosis factor a in the ambulatory treatment of ulcerative colitis. World J. Gastroenterol. 2015. Mar. 21; 21(11):3282-90.
  • 4. Brandse J.F., Van den Brink G.R., Wildcnberg M.E., Van der Kleij D., Rispens T., Jansen J.M., Mathot R.A., Ponsioen C.Y., Lowenberg M., D’Haens G.R. Loss of Infliximab Into Feces is Associated With Lack of Response to Therapy in Patients with Severe Ulcerative Colitis. Gastroenterology. 2015. Apr. 24. pii: S0016-5085(15)00572-7. doi: 10.1053/j. gastro.2015.04.016. [Epub ahead of print].
  • 5. Brochard C., Siproudhis L., Ropert A., Mallak A., Bretagne J.F., Bouguen G. Anorectal dysfunction in patients with ulcerative colitis: impaired adaptation or enhanced perception? Neurogastroenterol Motil. 2015. May. 4. doi: 10.1111/nmo. 12580. [Epub ahead of print],
  • 6. Bueno-Hernandez N., Niinez-Aldana M., Ascano-Gutierrez I., Yamamoto-Furusho J.K. Evaluation of diet pattern related to the symptoms of mexican patients with Ulcerative Colitis (UC): through the validity of a questionnaire. Nutr J. 2015. Mar. 14; 14(1):25.
  • 7. Christensen K.R., Steenholdt C., Brynskov J. Clinical outcome of adalimumab therapy in patients with ulcerative colitis previously treated with infliximab: a Danish single-center cohort study. Scand J. Gastroenterol. 2015. Apr. 10:1-7.
  • 8. Criscuoli V., Rizzuto M.R., Gallo E., Orlando A., Cottone M. Toxic megacolon and human Cytomegalovirus in a series of severe ulcerative colitis patients. J. Clin Virol. 2015. May; 66:103-6.
  • 9. Dahlen R., Magnusson M.K., Bajor A., Lasson A., Ung K.A., Strid H., Ohman L. Global mucosal and serum cytokine profile in patients with ulcerative colitis undergoing anti-TNF therapy. Scand J. Gastroenterol. 2015. Apr. 16:1-9.
  • 10. Dulai P.S., Mosli M., Khanna R., Levesque B.G., Sandborn W.J., Fea-gan B.G. Vedolizumab for the treatment of moderately to severely active ulcerative colitis. Pharmacotherapy. 2015. Apr.; 35(4):412-23.
  • 11. Galvan-Banqueri M., Vega-Coca M.D., Castillo-Munoz M.A., Beltran Calvo C., Molina Lopez T. Indirect comparison for Anti-TNF drugs in moderate to severe ulcerative colitis. Farm Hosp. 2015. Mar. 1; 39(n02):80-91.
  • 12. Gilardi D., Fiorino G., Allocca M., Bravata I., Danese S. Golimumab: clinical update on its use for ulcerative colitis. Drugs Today (Bare). 2015. Mar.; 51(3): 171-6.
  • 13. Hiraoka S., Kato J., Moritou Y., Takei D., Inokuchi T., Nakarai A., Takahashi S., Harada K., Okada H., Yamamoto K. The earliest trough concentration predicts the dose of tacrolimus required for remission induction therapy in ulcerative colitis patients. BMC Gastroenterol. 2015. Apr. 29; 15(1):53.
  • 14. Hoy S.M. Budesonide MMX®: A Review of Its Use in Patients with Mild to Moderate Ulcerative Colitis. Drugs. 2015. Apr. 29. [Epub ahead of print].
  • 15. Khalif I.L., Nanaeva B.A., Golovenko A.O., Golovenko O.V. [Long-term results of medical treatment in patients with a severe attack of ulcerative colitis]. Ter Arkh. 2015; 87(2):34-8.
  • 16. Lindsay J.O., Bergman A., Patel A.S., Alesso S.M., Peyrin-Biroulet L. Systematic review: the financial burden of surgical complications in patients with ulcerative colitis. Aliment Pharmacol Ther. 2015. Jun.; 41(1 1): 1066-78.
  • 17. Leifeld L., Rogler G., Stallmach A., Schmidt C., Zuber-Jerger I., Hartmann F., Plauth M., Drabik A., Hofstadter F., Dienes H.P., Kruis W.; Detect Dysplasia study group. White-Light or NBI Colonoscopy in Surveillance of Ulcerative Colitis: A Prospective Multicenter Study. Clin Gastroenterol Hepatol. 2015. May. 4. pii: SI542-3565(15)00631-X. doi: 10.1016/j.cgh.2015.04.172. [Epub ahead of print].
  • 18. Mace V., Ahluwalia A., Coron E., Le Rhun M., Boureille A., Bossard C., Mosnier J.F., Matysiak-Budnik T., Tarnawski A.S. Confocal laser endomicroscopy: A new gold standard for the assessment of mucosal healing in ulcerative colitis. J Gastroenterol Hepatol. 2015. Mar.; 30 Suppl 1:85-92.
  • 19. Magalhaes-Costa P., Matos L., Chagas C. Chronic tubulointerstitial nephritis induced by 5-aminosalicylate in an ulcerative colitis patient: a rare but serious adverse event. BMJ Case Rep. 2015. May. 2; 2015. pii: bcr2014207928. doi: 10.1136/bcr-2014-207928.
  • 20. Mosli M.H., MacDonald J.K., Bickston S.J., Behm B.W., Tsoulis D.J., Cheng J., Khanna R., Feagan B.G. Vedolizumab for Induction and Maintenance of Remission in Ulcerative Colitis: A Cochrane Systematic Review and Meta-analysis. Inflamm Bowel Dis. 2015. May; 21 (5): 1151 -9.
  • 21. Myrelid P., Dresland T. A reappraisal of the ileo-rectal anastomosis in ulcerative colitis. J. Crohns Colitis. 2015. Apr. 11. pii: jjv060. [Epub ahead of print].
  • 22. Narula N., Fine M., Colombel J.F., Marshall J.K., Rcinisch W. Systematic Review: Sequential Rescue Therapy in Severe Ulcerative Colitis: Do the Benefits Outweigh the Risks? Inflamm Bowel Dis. 2015. Apr. 1. [Epub ahead of print].
  • 23. Quddus A., Martin-Perez B., Schoonyoung H., Albert M., Atallah S. Toxic megacolon during pregnancy in ulcerative colitis: A case report. Int J Surg Case Rep. 2015. Apr. 29; 11:83-86.
  • 24. Puri A., Bharadwaj V., Sachdeva S. Extent of disease is a major outcome predictor in patients with ulcerative colitis and pregnancy. Indian J. Gastroenterol. 2015. Apr. 19. [Epub ahead of print].
  • 25. Sato S., Chiba T., Nakamura S., Matsumoto T. Changes in cytokine profile may predict therapeutic efficacy of infliximab in patients with ulcerative colitis. J. Gastroenterol Hepatol. 2015. May. 13. doi: 10.1111/jgh. 13008. [Epub ahead of print].
  • 26. Safroneeva E., Vavricka S.R., Fournier N., Straumann A., Rogler G., Schoepfer A.M. Prevalence and Risk Factors for Therapy Escalation in Ulcerative Colitis in the Swiss IBD Cohort Study. Inflamm Bowel Dis. 2015. Mar. 24. [Epub ahead of print]
  • 27. Takashima S., Kato J., Hiraoka S., Nakarai A., Takei D., Inokuchi T., Sugihara Y., Takahara M., Harada K., Okada H., Tanaka T., Yamamoto K.

Evaluation of Mucosal Healing in Ulcerative Colitis by Fecal Calprotectin Vs. Fecal Immunochemical Test. Am J. Gastroenterol. 2015. Mar. 31. doi: 10.1038/ajg.2015.66. [Epub ahead of print].

  • 28. Uchino M., Ikeuchi H., Matsuoka H., Bando T., Hirose K., Hirata A., Chohno T., Sasaki H., Yokoyama Y., Nakamura S., Nakamura Y., Take-sue Y. Surgery for Severe Ulcerative Colitis during Pregnancy: Report of Two Cases. Case Rep Gastroenterol. 2015. Mar. 27; 9(l):74-80.
  • 29. Yamamoto T., Shimoyama T., Bamba T., Matsumoto K. Consecutive Monitoring of Fecal Calprotectin and Lactoferrin for the Early Diagnosis and Prediction of Pouchitis after Restorative Proctocolectomy for Ulcerative Colitis. Am J. Gastroenterol. 2015. Apr. 28. doi: 10.1038/ajg.2015.129. [Epub ahead of print].
  • 30. Zhou Z., Dai C., Liu W.X. Anti-TNF-A therapy about infliximab and adalimamab for the effectiveness in ulcerative colitis compared with conventional therapy: a meta-analysis. Hepatogastroenterology. 2015. Mar.-Apr.; 62(138):309-18.
 
<<   СОДЕРЖАНИЕ   >>